Multidrug resistance.
Since we found verapamil as a multidrug resistance (MDR) reversing agent in 1981, many MDR reversing compounds have been reported. This type of drug must have strong effects with little side effects. We recently found MS-209 and PSC-833 as reversing agents. These two compounds interacted directly with P-glycoprotein, and showed a good MDR reversing effect in vitro and in vivo. MRK16, an antibody against P-glycoprotein, also showed a good therapeutic effect against drug resistant human tumors. MS-209, PSC-833 and the antibody against P-glycoprotein are interesting candidates for clinical use in the future.
Tsuruo
T
T
Institute of Molecular and Cellular Biosciences, University of Tokyo, Japan.
Tomida
A
A
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000276:immunology; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D018432:Drug Resistance, Multiple; D006801:Humans; D011804:Quinolines / Q000494:pharmacology*
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D011804:Quinolines; C087719:dofequidar